Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3587-3592

  Jin, Cong Guo ^a   Chen, Xiao Qun ^a   Li, Jia ^a   Wu, Zhi Pin ^a   Liu, Xin ^a   Wang, Xi Cai ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Cellular immune disorders; CIK cells; Improvement rate; Lung cancer; Maintenance time

Indexed keywords

EID: 84882660630     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3587     Document Type: Article

References (21)

1. Baas P, Belderbos J SA, van den Heuvel M (2011). Chemoradiation therapy in n on small cell lung cancer. Curr Opin Oncol, 23, 140-9.
2. Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5.
3. Bordón E, Henríquez-Hernández LA, Lara PC (2011). Role of CD4 and CD8 T-lymphocytes, B-lymphocytes and Natural Killer cells in the prediction of radiation-induced late toxicity in cervical cancer patients. Int J Radiat Biol, 87, 424-31.
4. Das S, Karim S, Datta Ray C (2007). Peripheral blood lymphocyte subpopulations in patients with cervical cancer. Int J Gynaecol Obstet, 98, 143-6.
5. Höltl L, Rieser C, Papesh C, et al (1999). Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendntic cell. J Urol, 161, 777-82.
6. Hongeng S, Petvises S, Worapongpaiboon S, et al (2003). Generation of CD3+CD56+ cytokine induced killer cells and their invitro cytotoxicity against pediatric cancer cells. Int J Hematol, 77, 175-9.
7. Hsu HS, Huang PI, Chang YL, et al (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer, 117, 2970-85.
8. Kim YJ, Lim J, Kang JS, et al (2010). Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res, 33, 1789-95.
9. Kuss I, Hathway B, Ferris RL, et al (2004). Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res, 10, 3755-62.
10. Levina V, Marrangoni A, Wan g T, et al (2010). Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res, 70, 338-46.
11. Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33.
12. Méndez R, Ruiz-Cabello F, Rodríguez T, et al(2007). Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherap. Cancer Immunol Immunother, 56, 88-94.
13. Shepherd FA, Douillard JY and Blumenschein GR Jr (2011). Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol, 6, 1763-73.
14. Shi M, Zhang B, Tang ZR, et al (2004). Autologous cytokine induced killer(CIK)cell therapy in clinical trial phaseIissafe in patients with primary hepatocellular carcinoma. World J Gastroenterol, 10, 1146-51.
15. Sievers E, Albers P, Schmidt-Wolf IG , et al (2004). Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol, 171, 114-9.
16. Urbanska K, Lanitis E, Poussin M, et al (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res, 72 ,1844-52.
17. Wang H, Zhou FJ, Wang QJ (2006). Efficacy of autologous renal tumor cell lysate- loaded dendritic cell vaccine in combination with cytokine- induced killer cells on advanced renal cell carcinoma- - a report of ten cases. Ai Zheng, 25, 625-30.
18. Wongkajornsilp A, Somchitprasert T, Butraporn R, et al (2009). Human cytokine- induced killer cells specifically infiltrated and etarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest, 27, 140-8.
19. Wu F, Wang ZB, Lu P, et al (2004). Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol, 30, 1217-22.
20. Xu Y, Liu LJ, Gao JM, et al (2010). Specific Anti- tumor Biological Activity of DCIK Cells. China Modern Doctor, 27, 360-2
21. Zhang H, Zhao Q, Zuo LF, et al (2007). The functional mechanism of CIK cell on ovarian carcinoma cell lines SKOV3/CDDP. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 23, 1167-9.